Federal officials on Wednesday alleged that Regeneron Pharmaceuticals (REGN) donated tens of millions of dollars to a foundation, but the payments were actually kickbacks to Medicare patients and designed to cover their out-of-pocket costs for a pricey eye medication.

In a lawsuit filed in federal court in Boston, the federal government accused Regeneron of using the Chronic Disease Fund to ensure that, in 2013 and 2014, Medicare patients did not have to make a co-payment or deductible for Eylea macular degeneration drug.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy